Markus Moehler

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque et al. · New England Journal of Medicine · 2023 · 541 citations · Full text

Medicine, Oncology, Pharmacology +16

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Markus Moehler, Mikhail Dvorkin, Narikazu Boku et al. · Journal of Clinical Oncology · 2020 · 223 citations · Full text

Medicine, Oncology, Pharmacology +15

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg et al. · New England Journal of Medicine · 2025 · 223 citations

Medicine, Oncology, Perioperative Medicine +14

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler et al. · Journal of Clinical Oncology · 2024 · 216 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +1